Abstract
Fabry disease resulting from a deficiency of α-galactosidase A leads to the accumulation of globotriaosylceramide in various organs. Because the disease is an X-linked recessive disorder, males tend to develop more symptoms and more severe symptoms than females. There are also some variants of Fabry disease, and cardiac variant (cardiac Fabry disease) has the dysfunctions only in heart. Cardiac manifestations in Fabry disease are initially symmetrical and concentric left ventricular hypertrophy, and later progressive cardiac dysfunction with localized thinning of the basal posterior wall. In recent years, enzyme replacement therapy has been performed as a treatment for Fabry disease, and the initiation of this therapy is expected before the cardiac fibrosis develops. Therefore, early diagnosis of Fabry disease is essential, and echocardiography is an indispensable tool for clinical practice of this disease. Then, it is necessary to remember this disease as a differential diagnosis when encountering unexplained left ventricular hypertrophy.
Similar content being viewed by others
References
Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–2.
Schiffmann R, Kopp JP, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743–9.
Nakatani S, Akaishi M, Asanuma T, et al. Guidelines from the Japanese society of echocardiography: guidance for the management and maintenance of echocardiography equipment. J Echocardiogr. 2015;13:1–5.
Masson C, Cissé I, Simon V, et al. Fabry disease: a review. Joint Bone Spine. 2004;71:381–3.
Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson–Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668–74.
Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047–53.
Desnick RJ, Banikazemi M, Wasserstein M. Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin Nephrol. 2002;57:1–8.
Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson–Fabry disease. Am J Cardiol. 2005;96:842–6.
Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Invest. 2004;34:236–42.
Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50–9.
Namdar M, Steffel J, Vidovic M, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart. 2011;97:485–90.
Hoigné P, Attenhofer Jost CH, Duru F, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol. 2006;111:413–22.
Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson–Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407–11.
Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50:2399–403.
Wu JC, Ho CY, Skali H, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010;31:1088–97.
Geske JB, Jouni H, Aubry MC, Gersh BJ. Fabry disease with resting outflow obstruction masquerading as hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014;63:e43.
Pieroni M, Chimenti C, DeCobelli F, et al. Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol. 2006;47:1663–71.
Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson–Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;51:2058–61.
Mundigler G, Gaggl M, Heinze G, et al. The endocardial binary appearance (‘binary sign’) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. Eur J Echocardiogr. 2011;12:744–9.
Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation. 2003;107:1978–84.
Shanks M, Thompson RB, Paterson ID, et al. Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr. 2013;26:1407–14.
Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4:592–601.
Boyd AC, Lo Q, Devine K, et al. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. J am Soc Echocardiogr. 2013;26:1415–23.
Nagueh SF. Anderson–Fabry disease and other lysosomal storage disorders. Circulation. 2014;130:1081–90.
Nieman M, Breunig F, Beer M, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart. 2010;96:1915–9.
Kawano M, Takenaka T, Otsuji Y, et al. Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry’s disease. Am J Cardiol. 2007;99:261–3.
Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med. 2001;345(1):9–16.
Weidemann F, Niemann Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524–9.
Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108:1299–301.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yuasa, T., Takenaka, T., Higuchi, K. et al. Fabry disease. J Echocardiogr 15, 151–157 (2017). https://doi.org/10.1007/s12574-017-0340-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12574-017-0340-x